TB-500 dosage in the research literature, read as it was administered.

TB-500 dosage and dosing in the research literature (animal models)

TB-500 dosage in the published record is research-context only: it describes what was administered to which species, by which route, at which dose — never a human protocol. Animal studies dosed full-length thymosin beta-4 across a wide range. Cardiac and neurological rodent models used roughly 6–12 mg/kg; the rat embolic-stroke dose-response study used 2, 12, and 18 mg/kg intraperitoneally and modeled an optimal dose near 3.75 mg/kg ^[4]. The mdx muscular-dystrophy study used 150 µg twice weekly intraperitoneally for six months ^[5].

Picogram-to-nanogram amounts are bioactive in vitro: about 10 pg was active in keratinocyte migration assays, and nanomolar thymosin beta-4 stimulated hair-follicle stem cells ^[3][5]. The single human exposure was the Phase 1 study, which dosed synthetic thymosin beta-4 intravenously at 42, 140, 420, and 1260 mg — a single dose, then daily for 14 days ^[6]. None of these are validated regimens for the TB-500 heptapeptide in humans. The "loading then maintenance" protocols that circulate in athletic and peptide-research communities are not derived from controlled human trials and have no published clinical validation ^[5].

Routes studied

Intraperitoneal injection predominates in rodent efficacy studies — it is how the wound, stroke, and dystrophy work delivered thymosin beta-4 ^[3][4][5]. Intravenous administration appears in the human Phase 1 and some cardiac models ^[6][2]. Topical and ophthalmic routes carry the dermal and corneal wound and dry-eye work, including the RGN-259 clinical-grade thymosin beta-4 formulation ^[5]. Subcutaneous and intramuscular routes appear in community research use but not in controlled human efficacy trials.

The route is not incidental: the FDA's stated safety concern for this fragment explicitly includes potential immunogenicity for certain routes of administration ^[1]. That is a regulatory reason the injectable context is treated differently from, say, a topical one — and it is one of the grounds cited for the substance's current 503A compounding status, covered on the TB-500 legal status and 503A access page. Note too that intraperitoneal dosing, the workhorse of the rodent record, is not a route used in routine human practice, which is one more step between the animal findings and any human application.

TB-500 half-life: what is and is not known

TB-500 half-life has no validated human pharmacokinetic value. There is no published human PK for the Ac-LKKTETQ heptapeptide ^[5]. In the intravenous Phase 1 of full-length thymosin beta-4, half-life increased with dose — the PK was dose-proportional — but that figure describes the ~4963 Da protein, not the ~889 Da fragment ^[6]. Anti-doping LC-MS work characterizes TB-500 and its metabolites in equine plasma and urine for detection purposes, not to establish a human elimination half-life ^[5]. So the honest statement is: no validated human half-life exists for the seven-mer, and the protein's dose-proportional PK is not a substitute for it. The acetylated seven-residue construct is more chemically robust than the full-length protein, but chemical robustness in a vial is not the same as a measured circulating half-life in a body, and no study has supplied the latter for the fragment ^[5].

How long does it take for TB-500 to work for injury healing?

No validated human timeline exists. The fastest objective signals come from rodent wound work, where re-epithelialization gains appeared within days — +42% by day 4, +61% by day 7 — but those used full-length thymosin beta-4 in rats, not the fragment in humans ^[3]. Translating a 4-to-7-day rodent wound figure into a human injury-recovery schedule is not supported by any controlled trial.

The dose-response shape: higher is not better

The most useful dosing lesson in the literature is not a number but a shape. In the rat embolic-stroke study, thymosin beta-4 improved neurological function at 2 and 12 mg/kg, but 18 mg/kg gave no significant benefit, and the authors modeled an optimal dose near 3.75 mg/kg ^[4]. That is a non-monotonic response: the curve rises, then falls. Past an optimum, more did not help — and in this model it stopped helping entirely.

This matters because the "loading then maintenance" rationale that circulates in athletic and peptide-research communities assumes the opposite — that piling on more, faster, compounds the effect ^[5]. The single best-characterized dose-response in the thymosin beta-4 record says that assumption is unsafe even on its own terms, before the fragment-vs-protein and the no-human-trial problems are added. There is no validated human dose for the seven-mer, and the animal data that exist do not endorse escalation.

Why the community protocols are not validated dosing

The numbers people share for TB-500 — weekly loading milligrams, maintenance schedules, cycle lengths — are not derived from controlled human trials and have no published clinical validation ^[5]. They are conventions, not findings. The only human dosing on record is the Phase 1 intravenous range for the full-length protein (42–1260 mg), and that was a safety and pharmacokinetic study, not a regimen anyone established as effective ^[6].

Layer in the identity problem and the gap widens: where a finding used full-length thymosin beta-4 at a milligram-per-kilogram dose in a rat, translating it to a fixed human milligram dose of the ~889 Da fragment crosses both a species line and a molecule line at once ^[5]. This page describes what was administered to which species, by which route, at which dose — and stops there. It does not convert any of it into a human protocol, because the literature does not support one.

Handling and material quality

TB-500 is supplied as a lyophilized (freeze-dried) powder for research use, reconstituted in bacteriostatic or sterile water and kept refrigerated ^[5]. As a short acetylated peptide it is more chemically robust than the full-length protein, but it remains subject to proteolysis and freeze-thaw degradation. A recurring, separate problem is identity: peptide purity and correct sequence — full-length versus fragment — are not guaranteed in unregulated supply, which both complicates interpreting anecdotal results and is one of the reasons community claims are hard to credit ^[5].